Skip to main content
. 2008 Sep 29;205(10):2235–2249. doi: 10.1084/jem.20080132

Figure 2.

Figure 2.

Lack of S100A9 affects generation of MDSCs under pathological conditions. (A) Enriched HPCs were isolated from bone marrow of S100A9 KO mice (KO) and their wild-type littermates (WT). Cells were cultured with GM-CSF and IL-4 for 5 d in complete culture medium or in the presence of EL-4 TCM. The cell phenotypes were evaluated by flow cytometry. Mean ± SD of the proportions of indicated cell populations from three mice are shown. (B) EL-4 cells (3 × 105) were injected s.c. into wild-type (WT) or S100A9 knockout (KO) mice and tumor size was measured. Anti-CD8 antibody (200 μg) was injected i.p. into KO mice 3 and 1 d before injection of tumor cells. The S100A9KO group included 12 mice, WT group 15 mice, and KO mice treated with anti-CD8 antibody 5 mice. Tumor size for each mouse is shown. (C) Phenotypes of splenocytes from wild-type (S100A9+/+) and knockout (S100A9−/−) mice 15 d after EL-4 cell injection were evaluated using multicolor flow cytometry. * represents statistically significant differences between the groups (P < 0.05). (D) Wild-type and S100A9 knockout mice were injected s.c. with 200 μl of CFA. The presence of Gr-1+CD11b+ cells was monitored in peripheral blood. Each group included 4 mice. Mean ± SD are shown. (E) Gr-1+CD11b+ cells in spleens of wild-type and S100A9 knockout mice on day 12 after CFA injection. Four mice per genotype were analyzed. * represents statistically significant differences between the groups (P < 0.05). (F) S100A9−/− mice were injected s.c. with 2 × 105 EL-4 tumor cells and then split into 2 groups of 5 mice. One group was left untreated (no transfer) and the other group was treated i.v. with 3 × 106 Gr-1+CD11b+ cells isolated from tumor-bearing wild-type mice (MDSC) on days 1, 3, 5, and 7 after tumor inoculation. Tumor size for each mouse is shown.